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ABSTRACT
Purpose: The aim of the study was to investigate risk factors of hearing impairments in 
preterm infants and analyze factors associated with discrepancies between neonatal 
hearing screening (NHS) and confirmatory test results. 
Methods: We analyzed the medical records of 352 preterm infants born at 23 to 32 
weeks’ gestational age (GA) who underwent both automated auditory brainstem 
response (aABR) and confirmatory ABR (cABR). 
Results: Mean GA, mean birth weight, the incidence of small for GA and cesarean 
section birth were significantly different between the pass and refer groups on aABR 
and the normal and abnormal groups of cABR. On univariate analysis, bronchopul­
monary dysplasia (odds ratio [OR], 2.74; 95% confidence interval [CI], 1.00 to 7.48), 
intraventricular hemorrhage (OR, 7.02; 95% CI, 1.59 to 31.05), and use of furosemide 
(OR, 3.84; 95% CI, 1.38 to 10.73) were the factors related to refer results on aABR. Peri­
ventricular leukomalacia (PVL; OR, 4.00; 95% CI, 1.39 to 11.52) and use of vancomycin 
(OR, 2.86; 95% CI, 1.22 to 6.73) were associated with abnormal cABR. Twenty­five 
(7.9%) infants had discrepant aABR and cABR results, particularly males and those in 
whom vancomycin was used.
Conclusion: PVL and use of vancomycin were confirmed as independent risk factors 
for hearing loss in infants born at less than 32 weeks’ GA. Also, discrepancies between 
the screening and confirmatory test may occur, especially among male infants and 
those in whom vancomycin was used. The hearing of infants must be assessed more 
carefully in such groups regardless of NHS results.
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INTRODUCTION
Hearing impairment (or hearing loss [HL]) is among the major neurodevelopmental 
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deficits associated with preterm birth1­3). The estimated incidence 
of bilateral permanent hearing loss (PHL) is 1 to 3 per 1,000 live 
births in the well infant population, and premature babies are at 
higher risk of hearing problems4). Despite the recent remarkable 
increase in survival of extremely preterm infants, the incidence of 
severe sensorineural hearing loss (SNHL) remained unchanged 
for over 30 years5). Gestational age (GA) and birth weight are 
inversely related to hearing pro blems1,2,6). 
Without appropriate stimuli reaching the auditory center of 
the brain, infants cannot achieve normal linguistic and social­
emotional development and later tend to experience psycholo­
gical and mental disorders2,7). Accordingly, it is critical that severe 
HL be detected in infants early on, especially premature infants. 
Although various screening protocols exist across countries and 
medical centers, the automated auditory brainstem response 
(aABR) is now widely used for screening for HL in newborn 
babies5,8). When the results of the screening test are suggestive of 
PHL, otoacoustic emissions and/or confirmatory auditory brain­
stem response (cABR) is performed to confirm actual hearing 
impairments. Both are noninvasive and can easily be performed 
on neonates and infants2,4,8). Among the different screening pro­
tocols, ABR is the most objective confirmatory technique7). 
In clinical practice, infants with congenital HL may receive a 
pass result on the neonatal screening test, meaning that the early 
detection of hearing impairment fails and timely treatment is 
not provided9). Effort is needed to identify the factors related to 
discrepancies between screening and confirmatory test results. 
By achieving the early recognition of infants with HL, we can 
provide effective treatments for them. The diagnosis should be 
made within 3 months after birth, as early intervention is needed 
before 6 months of age2,7). 
The Joint Committee on Infant Hearing reported several risk 
factors associated with PHL in 2000 and updated the list in 20078). 
Many other risk factors have been reported, including ototoxic 
drugs, prematurity, very low birth weight, a low Apgar score, and 
prolonged duration of mechanical ventilation1,4,6,10­15). 
In this study we investigated the risk factors of hearing impair­
ment in preterm infants born at less than 32 weeks’ GA and 
analyzed the factors that cause discrepancies between neonatal 
hearing screening (NHS) and confirmatory test results. 
MATERIALS AND METHODS 
The study was a retrospective single­center cohort study con­
ducted at the neonatal intensive care unit (NICU) of Severance 
Children’s Hospital, Yonsei University College of Medicine, 
Seoul, Korea. Of the 352 preterm infants born at 23 to 32 weeks’ 
GA between August 2008 and December 2017, five infants with 
genetic or major structural anomalies such as skeletal dysplasia, 
coarctation of the aorta, severe congenital ventriculomegaly, 
cleft palate, and Down syndrome were excluded. We reviewed 
the electronic medical records of the remaining 347 infants who 
underwent both aABR and cABR testing.
As soon as the general condition of infants allowed, NHS test­
ing using the aABR method was performed in the NICU prior to 
discharge. A reliable response from the infant at a threshold level 
of 35 dB on the test leads to a pass result; otherwise, a refer result 
is given. Regardless of the aABR results, all infants also underwent 
cABR testing performed by a specialized technician from the 
Department of Otolaryngology. HL was diagnosed when the 
cABR test result was ≥40 dB.
For analyses of risk factors for hearing impairment in general, 
information on a variety of factors along with those already known 
to be associated with hearing impairments like GA at birth, small 
for gestational age (SGA), and a low Apgar score were collected. 
SGA was defined as having a birth weight <10th percentile for the 
given GA. Some complications of prematurity reported by some 
studies as risk factors of HL in premature babies were cho sen 
for the analysis, including bronchopulmonary dysplasia (BPD), 
periventricular leukomalacia (PVL), intraventricular hemorrhage 
(IVH), culture­proven sepsis, retinopathy of prematurity, and 
patent ductus arteriosus. Prolonged duration of mechanical 
ventilation and some ototoxic drugs known to make hearing pro­
blems were also included. 
Discrepancies between the aABR and cABR tests were cate­
gorized into two groups: those with a refer result on the aABR 
test and a normal result on the cABR test (group of nonconcern 
[GN]); and those with a pass result on the aABR test and abnor­
mal result on the cABR test (group of concern [GC]). With a 
refer aABR test result in routine clinical settings, the infants are 
bound to undergo the cABR test within 3 months to ascertain 
whether there are actual hearing impairments; thus, this type of 
discrepancy would raise little safety concern in the clinical setting 
as with GN group. However, for the other group GC in clinical 
settings, where a pass result on the aABR test means no cABR test 
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required, there is a high probability that the infants might miss 
the opportunity of detecting HL in time for proper treatments. We 
focused our analysis only on this latter group.
Data are given as mean±standard deviation. For continuous 
variables with a normal distribution and homogeneous variance, 
t­tests were performed to compare two groups. For nominal 
variables, the chi­square test or Fisher’s exact test was performed. 
Binary and multiple logistic regression models were used to 
identify factors significantly associated with abnormal results on 
the aABR and cABR tests. Odds ratio (OR) and 95% confidence 
interval (CI) were also calculated. Statistical significance was 
considered at values of P<0.05. All statistical analyses were per­
formed using SPSS version 25.0 (IBM Co., Armonk, NY, USA). 
RESULTS
Of the 347 preterm infants, the mean GA at birth was 29.2±2.0 
weeks and mean birth weight was 1,232±367 g. A total of 267 
(76.9%) neonates were born by cesarean section, 52 (15.0%) were 
SGA, and 189 (54.5%) were male.
On the aABR method, 317 (91.4%) neonates showed a pass 
result and other 30 (8.6%) neonates had a refer result (Table 1). 
GA (29.3±2.0 weeks vs. 28.1±2.0 weeks, P=0.002), birth weight 
(1,261±358 g vs. 933±328 g, P<0.001), and 1­minute Apgar score 
(3.9±1.5 vs. 2.9±1.2, P=0.001) were significantly lower and a 
higher incidence of SGA infants (12.0% vs. 46.7%, P<0.001) and 
babies born by cesarean section (75.6% vs. 93.3%, P=0.037) were 
in the refer group. On the cABR test, a total of 41 (11.8%) neonates 
showed abnormal response and were diagnosed with an HL. 
As in the aABR group, GA (29.3±1.9 weeks vs. 28.4±2.3 weeks, 
P=0.011) and birth weight (1,259±364 g vs. 1,039±335 g, P<0.001) 
were lower in the abnormal cABR group. A higher incidence of 
infants born with SGA and by cesarean section was also reported 
in the abnormal group. 
Risk factors affecting hearing impairments ware shown in 
Table 2. By binary logistic regression modelling, moderate or 
severe BPD (OR, 2.74; 95% CI, 1.002 to 7.48), grade 3 or 4 IVH 
(OR, 7.02; 95% CI, 1.59 to 31.05), and use of furosemide for more 
than 14 days (OR, 3.84; 95% CI, 1.38 to 10.73) were significantly 
associated with abnormal aABR test results. In multiple logistic 
regression modelling with the adjustment for bias by prematurity 
using GA, grade 3 or 4 IVH (OR, 4.65; 95% CI, 1.13 to 19.17), 
and use of furosemide (OR, 3.91; 95% CI, 1.72 to 8.87) were still 
associated with a refer result on the aABR test. PVL (OR, 4.00; 95% 
CI, 1.39 to 11.52) and use of vancomycin for more than 5 days 
(OR, 2.86; 95% CI, 1.22 to 6.73) were associated with an abnormal 
cABR test on binary logistic regression. After the adjustment for 
GA, they remained significant risk factors for an abnormal cABR 
(OR, 4.03; 95% CI, 1.42 to 11.39 for PVL) (OR, 2.34; 95% CI, 1.02 to 
5.38 for use of vancomycin).
Factors related to an abnormal cABR result among patients 
with a normal aABR result are listed below (Table 3). Twenty­five 
(7.9%) infants had inconsistent aABR versus cABR test results, 
meaning that they passed the aABR test but had abnormal cABR 
test results. Infants who were male (OR, 3.05; 95% CI, 1.16 to 
8.07) and had a history of vancomycin use for more than 5 days 
(OR, 3.92; 95% CI, 1.45 to 10.55) were at significantly higher risk 
of having inconsistent results on the multiple logistic regression 
model with the adjustment for confounding factors like GA or 
birth weight.






Pass (n=317) Refer (n=30) Normal (n=306) Hearing loss (n=41)
Gestational age (wk) 29.3±2.0 28.1±2.0 0.002 29.3±1.9 28.4±2.3 0.011
Birth weight (g) 1,261±358 933±328 <0.001 1,259±364 1,039±335 <0.001
SGA 38 (12) 14 (47) <0.001 37 (12) 15 (37) <0.001
C­sec 239 (76) 28 (93) 0.037 231 (76) 36 (90) 0.045
Male sex 175 (55) 14 (47) 0.444 164 (54) 25 (61) 0.407
Apgar score­1 min 3.9±1.5 2.9±1.2 0.001 3.9±1.5 3.5±1.2 0.151
Apgar score­5 min 5.9±1.5 5.6±1.5 0.209 5.9±1.5 5.8±1.5 0.535
Values are expressed as mean±standard deviation or number (%).
Abbreviations: ABR, auditory brainstem response; SGA, small for gestational age; C­sec, cesarean section. 
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Table 2. Risk Factors Affecting Hearing Impairments
Variable
aABR
OR (95% CI) P-value
Confirmatory ABR








Mechanical ventilation ≥14 d 127 (40) 12 (40) 1.00 (0.46–2.14) 0.18 120 (39) 19 (46) 0.66 (0.25–1.77) 0.41
BPD (≥moderate) 140 (44) 20 (67) 2.74 (1.00–7.48) 0.05 137 (45) 23 (56) 1.26 (0.52–3.05) 0.61
PVL 14 (4) 5 (17) 3.54 (0.92–13.61) 0.07 13 (4) 6 (15) 4.00 (1.39–11.52) 0.04
IVH (≥grade 3) 6 (2) 4 (13) 7.02 (1.59–31.05) 0.01 6 (2) 4 (10) 3.16 (0.69–14.52) 0.14
Sepsis 9 (3) 1 (3) 0.19 (0.02–2.14) 0.18 9 (3) 1 (2) 0.30 (0.03–3.35) 0.33
ROP 47 (15) 8 (27) 1.60 (0.51–5.04) 0.42 47 (2) 8 (20) 0.86 (0.31–2.42) 0.77
PDA
Medical treatment 86 (27) 15 (50) 2.23 (0.90–5.47) 0.18 86 (28) 15 (37) 1.04 (0.46–2.37) 0.92
Surgical treatment 49 (16) 10 (33) 2.13 (0.73–6.24) 0.17 48 (16) 11 (27) 1.75 (0.69–4.42) 0.24
Furosemide ≥14 d 45 (14) 13 (43) 3.84 (1.38–10.73) 0.01 47 (15) 11 (27) 1.34 (0.51–3.52) 0.56
Vancomycin ≥5 d 40 (13) 3 (10) 0.65 (0.16–2.69) 0.57 34 (11) 9 (22) 2.86 (1.22–6.73) 0.02
Aminoglycoside ≥5 d 20 (6) 2 (7) 2.51 (0.49–12.94) 0.27 22 (7) 0 ­
Values are expressed as number (%).
Abbreviations: aABR, automated auditory brainstem response; OR, odds ratio; CI, confidence interval; ABR, auditory brainstem response; BPD, 
bronchopulmonary dysplasia; PVL, periventricular leukomalacia; IVH, intraventricular hemorrhage; ROP, retinopathy of prematurity; PDA, patent 
ductus arteriosus.
Table 3. Factors Correlated with Abnormal cABR Results Despite Normal aABR Results
Variable
Comparison of test results (n=317)
OR (95% CI) P-value
Concordant (n=292) Discrepant (n=25)
Gestational age (wk) 29.3±1.9 28.6±2.4 0.83 (0.53–1.31) 0.42
Birth weight (g) 1,271±363 1,148±285 1.00 (1.00–1.00) 0.65
SGA 33 (11) 5 (20) 1.68 (0.32–8.76) 0.54
Mode of delivery, C­sec 218 (75) 22 (88) 2.81 (0.80–9.95) 0.11
Male sex 156 (53) 19 (76) 3.05 (1.16–8.07) 0.02
Apgar score­1 min 3.9±1.5 3.9±1.1 1.27 (0.70–2.30) 0.43
Apgar score­5 min 5.8±1.5 5.9±1.3 1.03 (0.58–1.83) 0.92
Mechanical ventilation ≥14 d 115 (39) 12 (48) 0.66 (0.16–2.65) 0.55
BPD (≥moderate) 127 (44) 13 (52) 0.77 (0.22–2.64) 0.67
PVL 12 (4) 2 (8) 3.25 (0.47–22.29) 0.23
IVH (≥grade 3) 5 (2) 1 (4) 1.21 (0.08–17.71) 0.89
Proven sepsis 9 (3) 0 –
ROP 44 (15) 3 (12) 0.47 (0.10–2.27) 0.35
PDA
Medical treatment 78 (27) 8 (32) 0.99 (0.33–3.01) 0.99
Surgical treatment 43 (15) 6 (24) 1.81 (0.47–6.92) 0.39
Furosemide ≥14 d 40 (14) 5 (20) 1.51 (0.36–6.31) 0.57
Vancomycin ≥5 d 33 (11) 7 (28) 3.92 (1.45–10.55) 0.01
Aminoglycoside ≥5 d 20 (7) 0 ­
Values are expressed as mean±standard deviation or number (%).
Abbreviations: cABR, confirmatory auditory brainstem response; aABR, automated auditory brainstem response; OR, odds ratio; CI, confidence 
interval; SGA, small for gestational age; C­sec, cesarean section; BPD, bronchopulmonary dysplasia; PVL, periventricular leukomalacia; IVH, 
intraventricular hemorrhage; ROP, retinopathy of prematurity; PDA, patent ductus arteriosus. 
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DISCUSSION
Hearing impairment is among the most important conse­
quences of preterm birth. The NHS test is considered an effective 
method for the early detection of hearing impairments in infants; 
therefore, it should be of priority in neonatal care16,17). The goal of 
early detection and intervention for HL is to maximize linguistic 
competence and literacy development in children.
Routine NHS testing of all neonates in Korea began in 2007. 
Since then, the implementation of NHS programs for newborns 
has continued to grow. However, the sensitivity and accuracy 
of such NHS tests remain issues. The interpersonal and inter­
institutional variance of the test are also concerning, especially 
among preterm infants. To our knowledge, this is the first study 
to analyze risk factors for the discrepant results between aABR 
and cABR testing. Here we show the results of abnormal hearing 
screening tests in preterm infants in a single center in Korea over 
a 10­year period. 
The pathophysiology of HL in preterm infants is complex. 
Along with prematurity, SGA, and a low Apgar score, HL is com­
monly associated with multiple risk factors that can influence 
hearing in an additive fashion. A family history of hearing defi­
cits and genetic diseases that can affect the auditory system re­
portedly influence the degree of impairment. Thus, we excluded 
infants with any genetic diseases from the analysis of the discre­
pancies.
Other causes particularly important to HL in premature infants 
include ototoxic drugs such as aminoglycosides, vancomycin, 
and loop diuretics8,10,11,18). The ototoxicity of aminoglycoside de­
pends on treatment duration, serum peak and trough concentra­
tions, concomitant diseases, and the simultaneous administra­
tion of loop diuretics and/or vancomycin. Loop diuretics lead 
initially to reversible HL by blocking ion transport within the stria 
vascularis in the cochlea19). In this study, the use of loop diuretics 
was among the significant risk factors for an abnormal aABR 
result but not an abnormal cABR result. This might be explained 
by the reversibility of HL induced by the use of loop diuretics. 
If indeed there was enough time between the refer aABR result 
and the normal cABR result, the ototoxic damage done by loop 
diuretics may have been resolved by its discontinuation prior to 
performance of the cABR test.
Another risk factor for HL is exposure to the constant back­
ground noise generated by contemporary life­support equip­
ment in the NICU20). Robertson et al.5) showed that mechanical 
ventilation and prolonged oxygen supplementation were asso­
ciated with a high prevalence of PHL in extremely premature 
infants. Hille et al.21) similarly presented that assisted ventilation 
for ≥5 days is an independent risk factor for HL. However, in 
this study, mechanical ventilation lasting more than 14 days 
did not have an impact on the presence of HL. It is possible that 
the set point of 14 days was problematic, as only a few days of 
mechanical ventilation can contribute to hearing impairments as 
previously reported21). 
Infants with BPD invariably require prolonged periods of 
mechanical ventilation with an endotracheal tube, resulting in 
edema of the soft tissues around the Eustachian tube. As sug­
gested previously22), Eustachian tube dysfunction may exist 
in high­grade BPD patients, which would predispose them to 
effusions into the middle ears and, hence, hearing problems. In 
this study, infants with BPD were at a significantly higher risk of 
abnormal aABR results (OR, 2.74; 95% CI, 1.002 to 7.48; P<0.05). 
However, the cABR test results revealed no differences between 
the normal and abnormal groups. The possible explanations for 
this discrepancy include recovery from soft tissue swelling of 
the airway and Eustachian tube maturation, among others. This 
hypothesis can also be helpful in the analysis of conductive HL in 
BPD patients.
PVL, a white­matter injury affecting the brains of premature 
infants, is commonly associated with spastic diplegia, seizures, 
developmental delay, and visual and hearing impairments23,24) 
and results from hypoxic ischemic injury with or without con­
comitant infection. PVL is characterized by white­matter necro­
tic lesions, hypomyelination, microglial activation, astrogliosis, 
and neuronal death. White­matter abnormalities of the audi tory 
neural pathway can cause SNHL25). Similarly, PVL was signifi­
cantly associated with hearing impairments on the cABR test in 
this study. PVL could be a factor contributing to the discrepancy 
noted between the aABR and cABR test results because its symp­
toms usually appear gradually. 
The results of the aABR and cABR tests were analyzed by GA 
and birth weight. Both are widely known factors associated with 
HL in preterm infants1,26). Abnormal results on the aABR and 
cABR tests tended to occur in infants with a lower GA and lower 
birth weight. Consistency was noted between the results of the 
aABR test and the final diagnosis of HL on the cABR test for 10/78 
(12.8%) infants born at less than 28 weeks’ GA and 15/239 (6.3%) 
of infants born at 28 to 32 weeks’ gestation. We can expect that 
as GA at birth increases, the consistency between the aABR and 
131Neonatal Med 2020 August;27(3):126-132https://doi.org/10.5385/nm.2020.27.3.126
cABR results will be better maintained. 
We may fail to identify some patients with HL because of the 
imperfect nature of the NHS test. Since the risk of HL in preterm 
infants is greater than that in the normal group, despite the nor­
mal result of the screening test, we must carefully check for the 
presence of HL. In this study, male infants and those in whom 
vancomycin was used were significant risk factors for a discrep­
ancy between the NHS and confirmatory test results. There can 
be some sex­based differences in several aspects of the brain; 
with regard to the auditory system, men show longer delays on 
ABR tests than women, mainly because of the slightly longer 
length of the male cochlea27). No studies have focused on sexual 
differences in infants with congenital HL, and further studies with 
many more patients are needed to identify the exact correlation 
between sex and hearing impairments. 
Although debate persists, vancomycin is sometimes said to 
be an ototoxic drug10). Vestibular and/or cochlear damage asso­
ciated with tinnitus and SNHL have been reported in humans 
after the use of vancomycin. Some studies have reported that 
the concomitant use of aminoglycosides and vancomycin can 
cause hearing problems; however, in this study, no infants were 
administered both drugs. The use of vancomycin was a risk 
factor significantly associated with an abnormal cABR test result 
and could cause the discrepancy in aABR and cABR test results, 
probably by inducing a delayed HL. Also, despite the uncertainty 
of its ototoxic effects in the normal population, vancomycin may 
have a greater effect on hearing impairments in some relatively 
vulnerable groups, such as preterm infants. Furthermore, a rela­
tively short treatment duration of 5 days or the concomitant use 
of other ototoxic drugs like furosemide may have confounded the 
results. More studies are needed to confirm the possibility and 
mechanisms of ototoxicity with vancomycin use.
This study has several limitations. First, it was not a prospective 
cohort study; thus, some confounding factors could have affected 
the results. Second, the aABR and cABR tests were conducted 
at different times. Third, the sensitivities and specificities differ 
between the aABR and cABR; thus, some bias in risk factors 
may be unavoidable. Finally, the relatively small number of in­
fants with abnormal hearing could have caused some errors in 
the statistical analysis. Further studies with a greater sample of 
preterm infants should be conducted.
In conclusion, this study confirmed that PVL and use of van­
comycin for more than 5 days as independent risk factors for 
HL despite the adjustment for GA in infants born at less than 
32 weeks’ GA. Careful consideration of the use of vancomycin 
and a timely examination for HL are needed. We also found 
that, especially in male infants and those in whom vancomycin 
was used, a discrepancy existed between the screening and 
confirmatory test results. It is important to carefully assess high­
risk babies for false­negative results on the NHS test. Further 
studies on the risk factors of hearing impairments in premature 
babies are needed to ensure their normal future development.
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